Fritextsökning
Artiklar per år
Innehållstyper
-
Biosimilars bring price pressure, but are they sufficiently used?
When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely expensive treatments with biological drugs. So, how well has Swedish healthcare used biosimilars? The answer partly depends on whom you ask.
-
BioVentureHub CEO: “Companies with a high degree of interaction achieve greater success”
For the first time since its inception, AstraZeneca’s BioVentureHub can now recruit new companies, as some of its tenants have grown significantly and are leaving the hub. This is the message from the biohub’s CEO Magnus Björsne in an interview, in which he also highlights a study that points out that companies with a high degree of interaction with other companies achieve greater success.
-
Bioventurehubs vd: ”Företag som interagerar mycket når större framgång”
Astra Zenecas Bioventurehub kan för första gången sedan starten rekrytera nya bolag då några av hyresgästerna växt väsentligt och nu lämnar hubben. Det berättar biohubbens vd Magnus Björsne i en intervju där han också lyfter fram en studie som pekar på att företag som interagerar mycket med andra bolag når större framgångar.
-
A growing industry in Denmark: “One new life science company a week”
The life science sector in eastern Denmark continues to grow in the number of employees, as well as the number of companies. An emerging problem is the shortage of labour, a new report reveals.
-
Växande bransch i Danmark – "Ett nytt life science-företag i veckan"
Life science-sektorn i östra Danmark fortsätter att växa, både i antal anställda och antal företag. Ett uppseglande problem är bristen på arbetskraft, enligt en ny rapport.
-
Investments worth 40 billion in the Öresund region – “A huge investment wave”
A new report reveals that medical companies in the Oresund region are investing like never before.